Abstract: Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
Abstract: The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, prior to a second protein which is selected from the group comprising an E1A protein.
Abstract: Compositions containing therapeutically effective amounts of transfer factor and one or more compounds selected from glucosamine salts, dimethyl glycine, chondroitin, montmoril-lonite, curcumin, hyaluronic acid, boswellic acid, superoxide dismutase, methyl sulfonyl methane and glucans. Methods of treating inflammation and arthritis with the compositions of the present invention are also disclosed.
Abstract: Embodiments of the present invention are directed to a coated cell comprising a therapeutic cell and a plurality of targeting complexes coating the therapeutic cell and each of said targeting complexes comprising a homing molecule, a lipid moiety, and a spacer having from about 1 to about 10 amino acids and covalently linking the homing molecule to the lipid moiety and wherein the lipid moiety is non-covalently attached to the therapeutic cell. In some embodiments, the therapeutic cell is a stem cell. Embodiments of the invention are directed to methods of coating a therapeutic cell. Embodiments of the invention are directed to methods of treating diseases of the vasculature.
Type:
Grant
Filed:
June 7, 2010
Date of Patent:
November 12, 2013
Assignee:
Cell Targeting, Inc.
Inventors:
Joseph Wagner, Randell Young, David Fink
Abstract: The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions and therapeutic systems for treating an inflammatory condition.
Type:
Grant
Filed:
February 19, 2009
Date of Patent:
November 12, 2013
Assignee:
University of Rochester
Inventors:
Lianping Xing, Brendan F. Boyce, Edward M. Schwarz
Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
Abstract: The presently-disclosed subject matter includes polyurethane composites that include tissue component(s), as well as methods of making such composites and uses thereof. The polyurethane component can comprise a polyisocyanate prepolymer and a polyol. The tissue component can be a polysaccharide. Exemplary composites can be moldable and/or injectable, and can cure into a porous composite that provides mechanical strength and/or supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shaped areas, voids, or the like. Exemplary composites can be used for treating wounds.
Type:
Application
Filed:
April 16, 2013
Publication date:
November 7, 2013
Inventors:
Scott A. Guelcher, Andrea Hafeman, Jeffrey Davidson, Lillian M. Nanney, Elizabeth Adolph
Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.
Type:
Application
Filed:
March 25, 2013
Publication date:
November 7, 2013
Inventors:
Moti Harel, Qiong Tang, Trisha Rice, Kimberly Jennings, Brian Carpenter, Roger Drewes, Elizabeth Raditsis, January Scarbrough
Abstract: The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.
Type:
Grant
Filed:
April 10, 2009
Date of Patent:
November 5, 2013
Assignee:
Tekmira Pharmaceuticals Corporation
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Muthusamy Jayaraman
Abstract: An implant containing a collagen matrix embedded with chondrocyte-like cells, its use in repairing a chondral defect, and a method of preparing the implant.
Type:
Grant
Filed:
February 4, 2010
Date of Patent:
November 5, 2013
Inventors:
Hwa-Chang Liu, Feng-Huei Lin, Shing-Mou Lee, Chun-Che Yen
Abstract: The present invention features compositions and methods for introducing, into cells, nucleic acids whose expression results in chromosomal silencing. The nucleic acids are targeted to specific chromosomal regions where they subsequently reduce the expression of deleterious genes, or cause the death of deleterious cells. Where the nucleic acid sequence is a silencing sequence, it may encode an Xist RNA or other non-coding, silencing RNA. Accordingly, the present invention features, inter alia, nucleic acid constructs that include a transgene (e.g., a silencing sequence encoding an Xist RNA or other non-coding RNA that silences a segment of a chromosome); first and second sequences that direct insertion of the silencing sequence into a targeted chromosome; and, optionally, a selectable marker.
Abstract: The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage.
Type:
Application
Filed:
June 25, 2013
Publication date:
October 31, 2013
Inventors:
Rachid Bel-Rhlid, Karin Kraehenbuehi, Christophe Cavin, Thomas Wolfgang Raab, Nicolas Page
Abstract: Materials and methods for preparing three dimensional scaffolds are described. The materials, as improved high internal phase emulsions (HIPES), and the polymerization thereof may be suitable for injection prior to curing and when in an injectable form may be for site-directed in vivo use, curing after injection. In addition, said materials before curing may be engineered as a tissue substitution or enhancement and/or to include cell encapsulation. Said materials described herein form a monolith after curing and are biodegradable and porous after curing. Said materials are made from starting molecules using a process that does not rely on toxic solvents or monomers. Making of said materials to form the emulsion take advantage of one or more surfactants for HIPE stability. In addition, said materials cure at temperatures appropriate for use in an in vivo or in situ environment.
Abstract: The present invention is directed to a novel poly (diol citrates)-based coating for implantable devices. More specifically, the specification describes methods and compositions for making and using implantable devices coated with citric acid copolymers or citric acid copolymers impregnated with therapeutic compositions and/or cells.
Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.
Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.
Type:
Grant
Filed:
March 15, 2010
Date of Patent:
October 29, 2013
Assignee:
EGEN, Inc.
Inventors:
Kevin Polach, Jason Fewell, Khursheed Anwer
Abstract: The present invention relates to infant/young child nutrition. A set of nutritional compositions having beneficial effects to infants/young children is disclosed. The set of nutritional compositions comprises at least two compositions with varying amounts of components which impart a beneficial effect to the infants young/children. A nutrition kit for infants/young children comprising the set of nutritional compositions is also disclosed as well as a method for manufacturing the set of nutritional components. A dosage regimen is also disclosed.
Abstract: The present invention relates to the use of a composition containing stem cells as well as CD6 depleted stem cells for the induction of a tolerance to allogenic transplants and/or for the treatment of blood, immune, and cancer diseases for time-staggered application wherein first the stem cells are applied followed by application of the CD6 depleted stem cells. Furthermore, the present invention relates to a compound preparation containing stem cells and CD6 depleted stem cells.
Type:
Grant
Filed:
April 10, 2003
Date of Patent:
October 22, 2013
Assignee:
GSF-Forshungszentrum für Umwelt und Gesundheit, GmbH
Abstract: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.
Abstract: The present disclosure provides ex vivo-derived mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating bioreactor, such as a High Aspect Ratio Vessel (HARV) culture system. The bone constructs of the disclosure have utility in physiological studies of bone formation and bone function, in drug discovery, and in orthopedics.
Type:
Grant
Filed:
May 17, 2010
Date of Patent:
October 15, 2013
Assignees:
The United States of America as represented by the National Aeronautics and Space Administration, University of Houston, Universities Space Research Association
Inventors:
Mark S. F. Clarke, Alamelu Sundaresan, Neal R. Pellis
Abstract: The invention provides cosmetic compositions comprising microalgal biomass, whole microalgal cells, and/or microalgal oil in combination with one or more other cosmetic ingredients, and methods of making such compositions. In preferred embodiments, the microalgal components of the cosmetic compositions are derived from microalgal cultures grown heterotrophically and which comprise at least 10% oil by dry weight.
Abstract: The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses.
Type:
Grant
Filed:
June 3, 2011
Date of Patent:
October 8, 2013
Assignee:
AmebaGone, LLC
Inventors:
Marcin Filutowicz, Katarzyna Dorota Borys
Abstract: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.
Type:
Grant
Filed:
February 27, 2012
Date of Patent:
October 8, 2013
Assignee:
New York Medical College
Inventors:
Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Type:
Grant
Filed:
September 24, 2010
Date of Patent:
October 8, 2013
Assignee:
Central Iowa Health System
Inventors:
Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
Abstract: The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.
Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.
Type:
Grant
Filed:
October 25, 2005
Date of Patent:
October 8, 2013
Assignees:
Korea Institute of Radiological & Medical Sciences, Chung-Ang University Industry-Academy Cooperation Foundation
Inventors:
Young Sook Son, Hyun Sook Hong, Jae Chan Kim
Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.
Abstract: A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.
Type:
Grant
Filed:
November 27, 2012
Date of Patent:
September 24, 2013
Assignee:
TNTGamble, Inc.
Inventors:
Christopher London, Stephen J. Turner, Tanya Borek, Catherine Federici, Michael P. Hite
Abstract: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.
Abstract: The present invention relates to a composition including Bacillus subtilis strains 3A-P4 ATCC Accession No. PTA-6506, 22C-P1 ATCC Accession No. PTA-6508, and LSSA01 NRRL Accession No. NRRL B-50104. The present invention also relates to a method of administering an effective amount of a composition comprising Bacillus subtilis strains 3A-P4 ATCC Accession No. PTA-6506, 22C-P1 ATCC Accession No. PTA-6508, and LSSA01 NRRL Accession No. NRRL B-50104 to a calf.
Type:
Grant
Filed:
July 7, 2009
Date of Patent:
September 24, 2013
Assignee:
DuPont Nutrition Biosciences ApS
Inventors:
Christopher A. Wehnes, Keith J. Mertz, Mari Ellen Davis, Alexandra Helena Smith, Thomas G. Rehberger
Abstract: Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.
Type:
Application
Filed:
August 20, 2012
Publication date:
September 19, 2013
Inventors:
Colin R. Green, Bradford J. Duft, David L. Becker
Abstract: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases.
Abstract: A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.
Abstract: The present invention provides the use of ?arrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of ?arrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases.
Type:
Grant
Filed:
December 3, 2009
Date of Patent:
September 17, 2013
Assignee:
Shanghai Institutes for Biological Sciences, CAS
Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Type:
Grant
Filed:
September 9, 2010
Date of Patent:
September 17, 2013
Assignee:
Central Iowa Health System
Inventors:
Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
Abstract: Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described.
Type:
Grant
Filed:
May 7, 2009
Date of Patent:
September 10, 2013
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Thomas J. Wandless, Laura A. Banaszynski, Mark A. Sellmyer, Christopher H. Contag, Steven H. Thorne
Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×107 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.
Abstract: Intramolecular biosensors are disclosed, including PBP-based biosensors, comprising a ligand binding domain fused to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding ligand. At least one of the donor and fluorescent moieties may be internally fused to the biosensor such that both ends of the internally fused fluorophore are fixed. In addition, methods of improving the sensitivity of terminally fused biosensors are provided. The biosensors of the invention are useful for the detection and quantification of ligands in vivo and in culture.
Type:
Grant
Filed:
October 14, 2005
Date of Patent:
September 10, 2013
Assignee:
Carnegie Institution of Washington
Inventors:
Wolf B. Frommer, Sakiko Okumoto, Loren Looger, Marcus Fehr
Abstract: The invention provides a method for forming an immobilized agent gradient within a 3-dimensional porous scaffold. A 3-dimensional scaffold formed from a biocompatible material is provided. The surface of the scaffold and/or the agent is activated so as to allow binding of the agent to the scaffold. The activated scaffold is contacted with a solution containing the agent. Contact with the solution is maintained for a sufficient period of time to allow diffusion of the solution through a portion of the scaffold, thereby forming a desired gradient of the agent through the 3-dimensional scaffold.
Type:
Application
Filed:
February 25, 2013
Publication date:
September 5, 2013
Applicants:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, TRUSTEES OF TUFTS COLLEGE
Inventors:
Charu Vepari, David L. Kaplan, Gordana Vunjak-Novakovic
Abstract: The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localize in tumors and induce a tumoricidal response.
Abstract: A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.
Type:
Grant
Filed:
December 15, 2010
Date of Patent:
September 3, 2013
Assignees:
University of Saskatchewan, University of Guelph
Abstract: This invention is directed to a bone regeneration device including fascia and demineralized bone matrix mixed at a temperature not exceeding about 40° C. and lyophilized into the bone regeneration device, methods of preparing such a bone regeneration device and methods of treating bone defects using such a bone regeneration device.
Type:
Grant
Filed:
November 25, 2008
Date of Patent:
September 3, 2013
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Keith Matthew Kinnane, Susan J. Drapeau
Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from infections. The subject matter of the present inventions allows it to reduce absence from school or daycare. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of infections in children to reduce absence from school or daycare.
Type:
Application
Filed:
November 9, 2011
Publication date:
August 29, 2013
Applicant:
NESTEC S.A.
Inventors:
Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: Constructs and methods for immobilizing stem and other precursor cells, as well as other bioactive materials of therapeutic value on the surfaces of medical devices, such as bone, cartilage, spinal and tooth implants, are described herein. The present invention has broad application in the incorporation of bioactive and therapeutic materials in or on a medical implant or other interventional device, having particular value in enabling the real-time, utilization by medical personnel of bioactive materials extracted from the patient and subsequently reintroduced and immobilized in an implant device.
Type:
Grant
Filed:
July 6, 2012
Date of Patent:
August 27, 2013
Assignee:
Bioactive Surgical, Inc.
Inventors:
Richard H. Spedden, Judy Qiu, William Borch
Abstract: This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.
Type:
Grant
Filed:
July 15, 2011
Date of Patent:
August 27, 2013
Assignee:
Advanced Technologies and Regenerative Medicine, LLC
Abstract: Two novel strains of bacteria, C6-6 and C6-8, deposited in accordance with the Budapest Treaty, protect fish, such as by reducing mortality, against disease caused by bacteria, such as coldwater disease caused by Flavobacterium psychrophilum.
Abstract: The present invention relates to self-assembling membranes. In particular, the present invention provides self-assembling membranes configured for securing and/or delivering bioactive agents. In some embodiments, the self-assembling membranes are used in the treatment of diseases, and related methods (e.g., diagnostic methods, research methods, drug screening).
Type:
Grant
Filed:
February 14, 2008
Date of Patent:
August 20, 2013
Assignee:
Northwestern University
Inventors:
Ramille M. Capito, Helena S. Azevedo, Samuel I. Stupp
Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.
Type:
Grant
Filed:
December 5, 2011
Date of Patent:
August 20, 2013
Assignee:
Bioeos Limited
Inventors:
John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
Abstract: Strict anaerobic thermophilic bacterium belonging to the group of Thermoanaerobacter mathranii and mutants and derivatives thereof. The bacterium is particularly suitable for the production of fermentation products such as ethanol, lactic acid, acetic acid and hydrogen from lignocellulosic biomass.
Type:
Grant
Filed:
May 22, 2007
Date of Patent:
August 20, 2013
Assignee:
BioGasol IPR ApS
Inventors:
Marie Just Mikkelsen, Birgitte Kiaer Ahring, Tania Ivanova Georgieva